Clinical trials
Refractory Acute Leukemia clinical trials
Below are recruiting refractory acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 388 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT05210907RecruitingPhase 1
Hospital-made CD19 CAR-T for relapsed leukemia in children
This Phase 1 study tests a homemade (hospital-manufactured) immune treatment called CD19 CAR-T for children and teens with a type of leukemia that has come back or did not respond. It may help by targeting leukemia cells that carry the CD19 marker.
SeoulAges birth–25 years - NCT05703542RecruitingPhase 1
Testing BXCL701 for relapsed or resistant AML or MDS
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
Boston, MassachusettsAges 18 years+ - NCT05834244RecruitingPhase 1
New and relapsed AML treatment using azacitidine, venetoclax, and NK cells
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
Cleveland, OhioAges 18 years+ - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT06696833RecruitingEarly Phase 1
CD19-targeted CAR-T cell therapy for relapsed B-ALL
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets CD19 on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has not responded to treatment or has come back.
Suzhou, China, JiangsuAges 14 years+ - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 for adults and teens with relapsed B-ALL
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
Duarte, CaliforniaAges 12 years+ - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07403630Recruiting
Tumor chemogenomic profiler for cancer patients of all ages
This trial uses a new testing platform to analyze the genes and proteins in your tumor, aiming to find the most effective treatments for people with cancer that has come back, is not responding to treatment, or has spread. It is designed for both children and adults with any type of blood cancer or solid tumor.
Palermo, PalermoAges 1 year+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Chicago, IllinoisAges 18 years+ - NCT06429449RecruitingPhase 1
Mitoxantrone for venetoclax-resistant AML
This trial tests a re-purposed drug, mitoxantrone, for people whose AML has not responded to or has come back after standard frontline treatment. The goal is to see if this older drug can help overcome resistance to venetoclax.
Aurora, ColoradoAges 18–80 - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT05188170RecruitingPhase 1
Niclosamide for children and young adults with difficult leukemia
This Phase 1 study tests niclosamide, a medicine being studied as a new treatment, for pediatric and young adult AML that has come back or did not respond. It mainly focuses on whether the drug can be given safely and what dose might work best.
Palo Alto, CaliforniaAges 2–25 - NCT06265545Recruiting
Study for relapsed or hard-to-treat AML
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
TianjinAges Any age - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06616636RecruitingPhase 1
Rezatapopt and azacitidine for AML or MDS with a specific TP53 mutation
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
Tampa, FloridaAges 18 years+ - NCT07429461RecruitingEarly Phase 1
SYNCAR-100 for relapsed B-ALL
This trial tests a new CAR-T cell therapy called SYNCAR-100 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. If you qualify, you would receive an infusion of specially modified immune cells designed to attack and kill leukemia cells.
Hangzhou, ZhejiangAges 18–75 - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21
Hear when a new Refractory Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory acute leukemia?
- Yes. Clin2 currently lists 388 recruiting refractory acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Acute Myeloid Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Leukemia
- Refractory Transformed Chronic Lymphocytic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.